We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

212 hedge funds and large institutions have $3.44B invested in Neurocrine Biosciences in 2016 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 85 increasing their positions, 75 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more funds holding in top 10

Funds holding in top 10: 4 → 9 (+5)

40% more call options, than puts

Call options by funds: $22.7M | Put options by funds: $16.2M

13% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 75

5% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 37

3% less funds holding

Funds holding: 218 → 212 (-6)

27% less capital invested

Capital invested by funds: $4.7B → $3.44B (-$1.26B)

Holders
212
Holders Change
-6
Holders Change %
-2.75%
% of All Funds
5.65%
Holding in Top 10
9
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+125%
% of All Funds
0.24%
New
35
Increased
85
Reduced
75
Closed
37
Calls
$22.7M
Puts
$16.2M
Net Calls
+$6.55M
Net Calls Change
-$1.51M

Top Buyers

Rank Fund Capital Flow
1
SAM
Sectoral Asset Management
Quebec, Canada
+$48.9M
2
HM
HealthCor Management
New York
+$28.8M
3
Citadel Advisors
Citadel Advisors
Florida
+$26.9M
4
First Trust Advisors
First Trust Advisors
Illinois
+$25.3M
5
Goldman Sachs
Goldman Sachs
New York
+$22.8M

Top Sellers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$33.1M
2
PC
PointState Capital
New York
-$29.7M
3
RIM
RS Investment Management
California
-$23.8M
4
CCI
Columbus Circle Investors
-$18.2M
5
VAM
Visium Asset Management
New York
-$13.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
NIP
101
Nicholas Investment Partners
California
$2.6M -$497K -12,537 -16%
BG
102
Bellevue Group
Switzerland
$2.57M +$2.58M +65,000 New
BlackRock
103
BlackRock
New York
$2.53M -$373K -9,408 -13%
ACM
104
Asymmetry Capital Management
California
$2.5M +$885K +22,300 +55%
State Board of Administration of Florida Retirement System
105
State Board of Administration of Florida Retirement System
Florida
$2.4M -$270K -6,800 -10%
RPAM
106
Rhenman & Partners Asset Management
Sweden
$2.37M +$2.38M +60,000 New
MLICM
107
Metropolitan Life Insurance Company (MetLife)
New York
$2.36M +$12.7K +320 +0.5%
GH
108
GAM Holding
Switzerland
$2.35M +$381K +9,600 +19%
BNP Paribas Asset Management
109
BNP Paribas Asset Management
France
$2.34M +$2.35M +59,241 New
IGIM
110
I.G. Investment Management
Manitoba, Canada
$2.25M +$476K +12,000 +27%
DBG
111
De Burlo Group
Massachusetts
$2.07M -$35.7K -900 -2%
AIMCA
112
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$1.99M -$4M -100,722 -67%
AIG
113
American International Group
New York
$1.98M -$54.8K -1,380 -3%
CSS
114
Cubist Systematic Strategies
Connecticut
$1.91M +$1.69M +42,539 +746%
PPA
115
Parametric Portfolio Associates
Washington
$1.89M +$975K +24,558 +105%
PA
116
Profund Advisors
Maryland
$1.86M -$431K -10,859 -19%
NC
117
Nexthera Capital
New York
$1.66M +$595K +15,000 +56%
TAM
118
Tocqueville Asset Management
New York
$1.63M +$631K +15,900 +63%
Two Sigma Advisers
119
Two Sigma Advisers
New York
$1.58M +$413K +10,400 +35%
Morgan Stanley
120
Morgan Stanley
New York
$1.48M -$1.12M -28,243 -43%
PAM
121
Panagora Asset Management
Massachusetts
$1.48M +$1.3M +32,780 +714%
ACI
122
Alpha Cubed Investments
California
$1.42M – – –
UBS Group
123
UBS Group
Switzerland
$1.39M -$765K -19,270 -35%
CAM
124
ClariVest Asset Management
California
$1.36M +$52.9K +1,332 +4%
RFC
125
Russell Frank Company
Washington
$1.35M -$766K -19,304 -36%
3 4
5
6 7

NBIX Hedge Fund Activity: Q1 2016 in Review

212 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2016, worth a combined $3.44B — down 27% from $4.7B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of NBIX and 35 opened new positions — a net loss of 2 holders — while 75 trimmed existing stakes and 85 added.

The largest buyer was Sectoral Asset Management, adding an estimated $48.9M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $33.1M sold.

  • 212 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2016, down from 218 in Q4 2015.
  • Funds reported $3.44B of Neurocrine Biosciences stock for Q1 2016, down 27% quarter-over-quarter.
  • 35 funds opened new Neurocrine Biosciences positions in Q1 2016 and 37 closed out, a net change of -2 holders.
  • The largest Neurocrine Biosciences buyer in Q1 2016 was Sectoral Asset Management, an estimated $48.9M added.
  • The largest Neurocrine Biosciences seller in Q1 2016 was Lord, Abbett & Co, an estimated $33.1M sold.

Based on aggregated 13F filings for Q1 2016.